The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Assessment of MRD using hsFCM in the Phase III GAIA (CLL13) trial
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, shares some findings from the post-hoc analysis of minimal residual disease (MRD) using high-sensitivity flow cytometry (hsFCM) in the Phase III GAIA (CLL13) Trial (NCT02950051). In this video, Dr Eichhorst summarizes findings from this analysis, explaining in detail the different levels of MRD that were detected using hsFCM in the various venetoclax-based treatment combinations compared to chemoimmunotherapy. Based on this analysis, hsFCM improves detection of low levels of MRD and can detect past the conventional level of 10-4, which has promising implications for the future of chronic lymphocytic leukemia (CLL). This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, 2021.
